Multiple myeloma (MM) | Flatiron Health

Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Li L, Tang S, Reichman W, Kauffman MG, Shah JJ, Shacham S, Lonial S.

June 2019

Abstract

ASCO Annual Meeting

Burden of thrombocytopenia in adult cancer patients receiving chemotherapy →

Soff GA, Shaw J, Kilpatrick K, Marongiu A, Park J.

June 2019

Abstract

ASCO Annual Meeting

Development and initial validation of a prognostic score based on structured data from EHRs →

Backenroth D, Haimson JD, Meropol NJ, Baxi SS.

April 2019

Abstract

AACR Annual Meeting

Flatiron-authored

Initiation and interruption in intravenous bisphosphonate therapy among patients with multiple myeloma in the United States →

McGrath LJ, Hernandez RK, Overman R, Reams D, Liede A, Brookhart MA, O’Donnell E, Leah J

December 2018

Manuscript

Cancer Medicine

The Real-World Frequency of 24-Hour Urine Protein Electrophoresis (UPEP), Serum Free Light Chain (SFLC), and Serum Protein Electrophoresis (SPEP) Testing in Patients with Multiple Myeloma (MM) →

Foster R, Lipitz NG, Torres AZ, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Real-World Disparities in Daratumumab Utilization for Patients with Relapsed or Refractory Multiple Myeloma (MM) →

Maignan K, Backenroth D, McQuarrie NA, Lipitz NG, Williams E, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Dynamic Changes in International Staging System As a Predictor of Survival Outcome in Patients with Advanced Multiple Myeloma →

Hong JL, Crossland V, Galaznik A, Dolin P

December 2018

Abstract

American Society of Hematology Annual Meeting

Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM →

Chari A

December 2018

Abstract

Blood Journal

Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies →

Li B, Ren K, Shen L, Hou P, Sun Z, Di Bacco A, Hong JL, Galaznik A, Dash AB, Crossland V, Dolin P, Szalma S

December 2018

Abstract

Blood Journal

Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis →

Chari A, Ung B, Tian M, Agarwal A, Parikh K

December 2018

Abstract

Blood Journal

Validation of Clinical vs Algorithmic Definition of Line of Therapy in Multiple Myeloma →

Black J, Ogbu U, Wassner Fritsch E, Byon J, Yi J, Lu M

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Patterns of Bisphosphonate Treatment Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the USA: Observations from Real-World Data →

Kim C, Hernandez RK, Cyprien L, Liede A, Cheng P

August 2018

Manuscript

Supportive Care in Cancer

Maintenance (MT) Treatment (tx) after Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction and Stem Cell Transplant (SCT) in High-Risk (HR) Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Analysis →

Fonseca R, Parikh K, Ung B, Ni Q, Agarwal A

June 2018

Abstract

ASCO Annual Meeting

Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database →

Chari A, Ung A, Abouzaid S, Ni Q, Parikh K, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT) →

Fonseca R, Parikh K, Ung B, Ni Q, Abouzaid S, Agarwal A

December 2017

Abstract

American Society of Hematology Annual Meeting

Patterns and Predictors of Initiation of Intravenous Bisphosphonates Among Patients with Multiple Myeloma in the United States →

McGrath L, Hernandez RK, Overman R, Reams D, Liede A, Brookhart A

December 2017

Abstract

American Society of Hematology Annual Meeting

Multiple Myeloma Patients and Risk of Skeletal Related Events – Real-World Evidence in US Oncology Clinics →

Bhatta S, Cyprien L, Fonseca R, Hernandez RK, Kim C

December 2017

Abstract

American Society of Hematology Oncology

Bone Targeting Agent Treatment Patterns Among Patients with Multiple Myeloma Treated at Oncology Clinics Across the United States: Observations from Real-World Data →

Kim C, Hernandez RK, Cheng P, Smith J, Cyprien L, Liede A

December 2016

Abstract

American Society of Hematology Annual Meeting

Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma →

Calkins G, Kohansimeh J, Krishna A, Green R, Curtis MD, Lindberg F, Jaskiw A, Larrabee K, Terry M, Feinstein RN, Plotkin L, Palladino ML, Nicacio L

June 2015

Abstract

EHA Learning Center

Flatiron-authored